Company & Sponsor Intelligence

Bristol-Myers Squibb

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials9

Recruiting2

Completed6

Countries1

Therapeutic footprint

alzheimersdepressionpain_neuropathy

Indexed studies

NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
alzheimers · United StatesPHASE3

NCT00979316Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects
alzheimers · United StatesPHASE1

NCT00726726Drug Interaction Study With a Potential Alzheimer's Disease Compound
alzheimers · United StatesPHASE1

NCT01309945Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
depression · United StatesPHASE2

NCT00890890A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease
alzheimers · United StatesPHASE2

NCT00683423BMS-741672 for Diabetic Neuropathic Pain
pain_neuropathy · United StatesPHASE2

NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
alzheimers · United StatesPHASE3

NCT01454115Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163
alzheimers · PHASE1

NCT01057030Multiple Dose Japanese Bridging Study
alzheimers · United StatesPHASE1

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →